MaaT Pharma reports safety interim analysis from trial of microbiome therapy

MaaT Pharma reports safety interim analysis from trial of microbiome therapy

Submitted by admin on April 9, 2025 - 11:25am
Source: 
Clinical Trials Arena
News Tags: 
MaaT Pharma
clinical trials
MaaT033
stem cell transplant
microbiome
Headline: 
MaaT Pharma reports safety interim analysis from trial of microbiome therapy
snippet: 

French biotechnology company MaaT Pharma has reported positive results from an interim safety analysis of its Phase IIb PHOEBUS trial of MaaT033 in subjects undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT).

Do Not Allow Advertisers to Use My Personal information